Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| XRTX | PRESS-RELEASE | neutral | 4/10 | XORTX Therapeutics announced plans to submit an IND to the FDA in Q4 2026 for its XRx-026 gout program (XORLO formulatio | Sep 18, 2026 |
| ELAB | 8-K | neutral | 4/10 | PMGC Holdings Inc. (ELAB) announced a binding payment agreement with Longevity Health Holdings to convert the 5% net sal | Sep 18, 2026 |
| ELAB | PRESS-RELEASE | neutral | 4/10 | PMGC Holdings entered a payment agreement with Longevity Health Holdings converting its 5% net sales royalty from the El | Sep 18, 2026 |
| ABEO | PRESS-RELEASE | bullish | 6/10 | Abeona Therapeutics issued a press release congratulating Ultragenyx on FDA approval of FAYUVI (UX111) for MPS IIIA, a g | Sep 18, 2026 |
| BLSM | 8-K | bearish | 6/10 | BlossomHill Therapeutics reported Q2 2026 net loss of $23.8M ($-8.75/share), significantly wider than the $-0.77 consens | Sep 18, 2026 |
| BSEM | PRESS-RELEASE | bearish | 6/10 | BioStem Technologies announced a $40 million Committed Equity Facility (CEF) with Roth Principal Investments, allowing t | Sep 18, 2026 |
| BLSM | PRESS-RELEASE | neutral | 5/10 | BlossomHill Therapeutics reported Q2 2026 net loss of $23.8M ($-8.75/share), far exceeding the consensus estimate of $-0 | Sep 18, 2026 |
| AZN | 6-K | bullish | 4/10 | AstraZeneca CEO Pascal Soriot purchased 60,000 ordinary shares at £121.02 per share on 14 September 2026, a GBP 7.26 mil | Sep 18, 2026 |
| CDT | PRESS-RELEASE | neutral | 4/10 | CDT Equity announced a partnership with QIMA Life Sciences to explore tapinarof (VTAMA®) combinations in autoimmune skin | Sep 18, 2026 |
| RDY | 6-K | neutral | 4/10 | Dr. Reddy's has entered into an exclusive distribution and marketing agreement with Takeda for Qdenga, a dengue vaccine, | Sep 18, 2026 |
| ICLR | CLUSTER | bearish | 4/10 | Two ICON PLC directors sold a combined $1.45M in open-market transactions on September 17, 2026, at ~$175/share. The sal | Sep 18, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a 6-K announcing that Non-Executive Director Lawrence Gozlan will present at the ASX SMIDcap | Sep 18, 2026 |
| CDT | EFFECT | neutral | 5/10 | CDT Equity Inc.'s S-1 registration statement (File No. 333-298808) became effective on September 17, 2026, clearing the | Sep 18, 2026 |
| ACXP | EFFECT | bearish | 5/10 | The SEC declared effective Acurx Pharmaceuticals' S-1 registration statement (File No. 333-298801) on September 17, 2026 | Sep 18, 2026 |
| ETRA | EFFECT | bullish | 7/10 | Electra Therapeutics' S-1 registration statement for its IPO of common stock has been declared effective by the SEC as o | Sep 18, 2026 |
| BKHA | EFFECT | neutral | 5/10 | The SEC declared effective a registration statement (S-4) filed by Black Hawk Acquisition Corp and Vesicor Therapeutics, | Sep 18, 2026 |
| TENX | CLUSTER | bullish | 5/10 | Three insiders at Tenax Therapeutics, including the CEO and CFO, made open-market purchases totaling $122K over a one-we | Sep 17, 2026 |
| TVTX | CLUSTER | bearish | 4/10 | Two Travere insiders sold a combined $377K in open-market sales over a one-week window. Director Jeffrey Meckler sold $1 | Sep 17, 2026 |
| ETRA | PRESS-RELEASE | bullish | 7/10 | Electra Therapeutics priced its upsized IPO of 23,333,334 shares at $15.00 per share, raising approximately $350.0 milli | Sep 17, 2026 |
| PVLA | CLUSTER | bearish | 6/10 | Director George M. Jenkins sold a total of ~27,500 shares worth ~$4.17M in open-market sales over three trading days (Se | Sep 17, 2026 |
| CBIO | CLUSTER | neutral | 3/10 | CEO Joshua Brumm and President/COO Jonathan McNeill sold a combined $195K of CBIO stock on September 18, 2026, at $16.71 | Sep 17, 2026 |
| ROIV | CLUSTER | neutral | 2/10 | Two Roivant directors sold a combined ~$359K in open-market transactions on September 15, 2026, at ~$39.65-$40.45 per sh | Sep 17, 2026 |
| ROIV | CLUSTER | neutral | 2/10 | Two Roivant directors sold a combined ~$359K in open-market sales on September 15, 2026. The total value is ~0.1% of mar | Sep 17, 2026 |
| ROIV | CLUSTER | neutral | 2/10 | Two Roivant Sciences directors sold a combined ~$359K in open-market transactions on September 15, 2026. The sales are m | Sep 17, 2026 |
| INBX | CLUSTER | bullish | 5/10 | Inhibrx Biosciences (INBX) insider cluster shows a director (Kayyem) making a $500K open-market purchase at $100/share, | Sep 17, 2026 |
| PHVS | 144 | bearish | 5/10 | Berndt Modig, an officer and director of Pharvaris N.V., filed a Form 144 notice of intent to sell up to 300,000 common | Sep 17, 2026 |
| HALO | CLUSTER | neutral | 2/10 | CEO Helen Torley exercised 20,000 options at $18.41 and immediately sold 20,000 shares on the open market at ~$107.15, n | Sep 17, 2026 |
| MEOH | SC 13G/A | neutral | 3/10 | Sunil Jagwani and Key Group Long Term Investments LP filed Amendment No. 3 to their Schedule 13G, reporting beneficial o | Sep 17, 2026 |
| SION | 144 | bearish | 5/10 | RA Capital Healthcare Fund LP, a 10% stockholder of Sionna Therapeutics, filed a Form 144 on September 17, 2026, indicat | Sep 17, 2026 |
| TPST | 8-K | bullish | 6/10 | Tempest Therapeutics entered into an exclusive option agreement with Hebei Senlang Biotechnology to license Senlang's CD | Sep 17, 2026 |